Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MEXATE is an antimetabolite that inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate synthesis and interfering with DNA, RNA, and protein synthesis. It also inhibits thymidylate synthetase and has immunomodulatory and anti-inflammatory effects.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Rheumatoid arthritis (moderate to severe active disease in adults),Polyarticular juvenile idiopathic arthritis,Psoriasis (severe, recalcitrant, disabling),Neoplastic diseases: gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole; acute lymphocytic leukemia (ALL); meningeal leukemia; Burkitt lymphoma; advanced non-Hodgkin lymphomas; mycosis fungoides; advanced head and neck cancer; osteosarcoma (adjunctive treatment),Off-label: ectopic pregnancy, inflammatory bowel disease, graft-versus-host disease, sarcoidosis, systemic lupus erythematosus, vasculitis
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
10-25 mg/m2 orally or intramuscularly once weekly for rheumatoid arthritis; 50 mg/m2 intravenously once weekly for psoriasis; 30-40 mg/m2 intravenously weekly for certain cancers (dose varies by protocol).
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life is 3-10 hours for low-dose therapy (≤30 mg/m²). For high-dose therapy (>100 mg/m²), terminal half-life extends to 8-15 hours due to saturable elimination. A third, prolonged terminal phase (8-72 hours) is observed in some patients due to enterohepatic recirculation.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Methotrexate is primarily metabolized by hepatic aldehyde oxidase to 7-hydroxymethotrexate. It undergoes polyglutamation intracellularly. Less than 10% is metabolized by cytochrome P450 enzymes. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Renal excretion of unchanged drug is the primary route of elimination, accounting for 80-90% of the dose. Biliary/fecal excretion is minor (<10%).
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
50-60% bound, primarily to albumin.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
0.4-0.8 L/kg (total body water). Vd increases with dose, indicating tissue distribution.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Oral: 30-70% (dose-dependent, saturable absorption). Intramuscular: 80-100%. Subcutaneous: approximately 100%.
Intravenous administration yields 100% bioavailability.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Child-Pugh A: 75% of normal dose; Child-Pugh B: 50% of normal dose; Child-Pugh C: contraindicated.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
For leukemia: 20-40 mg/m2 orally or intravenously once weekly; for juvenile idiopathic arthritis: 10-15 mg/m2 orally once weekly (max 25 mg/week).
Safety and effectiveness in pediatric patients have not been established.
Start at lowest effective dose (e.g., 5-7.5 mg/week) with close monitoring of renal function, hepatic function, and hematologic parameters due to increased toxicity risk.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
Boxed Warning: Methotrexate (MEXATE) can cause severe or fatal toxicities including bone marrow suppression, hepatic fibrosis/cirrhosis, pulmonary fibrosis, renal failure, and ulcerative stomatitis. Fatalities have been reported with inadvertent daily dosing instead of weekly. For rheumatoid arthritis and psoriasis, use only in patients with severe disease. Monitor for toxicity closely. Advise patients about risks of fatal toxicity.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Severe hematologic toxicity (bone marrow suppression, pancytopenia), hepatotoxicity (fibrosis, cirrhosis, acute hepatitis), pulmonary toxicity (pneumonitis, fibrosis), renal toxicity, gastrointestinal toxicity (stomatitis, ulceration), neurotoxicity (leukoencephalopathy), opportunistic infections, tumor lysis syndrome, photosensitivity, and dermatologic reactions. Avoid concomitant NSAIDs, salicylates, and nephrotoxic drugs. Monitor CBC, LFTs, creatinine, and chest imaging. Use caution in elderly, debilitated, or patients with renal impairment, ascites, or pleural effusions.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Hypersensitivity to methotrexate, alcohol abuse, pre-existing liver disease (including hepatitis), renal impairment (creatinine clearance < 60 m L/min), pre-existing bone marrow suppression, immunodeficiency, active infections (e.g., tuberculosis), pregnancy, breastfeeding, lactation.
None known.
Avoid alcohol due to increased hepatotoxicity risk. No specific food restrictions; however, maintain adequate hydration. Folate-rich foods do not interfere but supplemental folic acid may be prescribed to reduce side effects.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
Category X. 1st trimester: High risk of CNS, craniofacial, and skeletal malformations. 2nd and 3rd trimesters: Fetal growth restriction, oligohydramnios, and neonatal pancytopenia.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
Contraindicated. Methotrexate is excreted in human milk; M/P ratio approximately 0.08. Potential for severe neonatal toxicity.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
Not applicable; contraindicated in pregnancy. If inadvertent exposure, discontinue and refer for fetal assessment.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Mexate (methotrexate) is a folate analog antimetabolite used in high doses for malignancy and low doses for autoimmune diseases. Reserve leucovorin rescue for high-dose protocols to prevent severe myelosuppression. Monitor renal function and methotrexate levels; adjust hydration and alkalinization to prevent precipitation in renal tubules. Avoid concurrent NSAIDs and proton pump inhibitors which reduce methotrexate clearance. Screen for pregnancy before initiation. Administer weekly in low-dose regimens for rheumatoid arthritis to avoid acute toxicity.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Take exactly as prescribed—do not increase dose or frequency. Overdose can be fatal.,Avoid alcohol completely while on this medication.,Report any signs of infection, unusual bleeding, bruising, or mouth sores immediately.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not take NSAIDs or aspirin without consulting your doctor.,Stay well hydrated; drink plenty of fluids unless otherwise instructed.,Avoid live vaccines during treatment.,Keep all follow-up appointments for blood tests and monitoring.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE vs COLUMVI, answered by our medical review team.
MEXATE is a Antineoplastic Agent that works by MEXATE is an antimetabolite that inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate synthesis and interfering with DNA, RNA, and protein synthesis. It also inhibits thymidylate synthetase and has immunomodulatory and anti-inflammatory effects.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE is: 10-25 mg/m2 orally or intramuscularly once weekly for rheumatoid arthritis; 50 mg/m2 intravenously once weekly for psoriasis; 30-40 mg/m2 intravenously weekly for certain cancers (dose varies by protocol).. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE is classified as Category C. Category X. 1st trimester: High risk of CNS, craniofacial, and skeletal malformations. 2nd and 3rd trimesters: Fetal growth restriction, oligohydramnios, and neonatal pancytopenia.. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.